JS

John Soong

Chief Medical Officer

Senhwa Biosciences

Therapeutic Areas

Senhwa Biosciences Pipeline

DrugIndicationPhase
Silmitasertib (CX-4945)CholangiocarcinomaPhase II
Pidnarulex (CX-5461)Solid Tumors with HRDPhase I